中国组织工程研究与临床康复2011，Vol.15Issue(6)：1103-1106,4.DOI:10.3969/j.issn.1673-8225.2011.06.034
基于乳腺癌干细胞的临床治疗进展
Progress in the clinical treatment based on breast cancer stem cells
任远 1李泽桂2
作者信息
- 1. 解放军第三军医大学学员旅四队,重庆市,400038
- 2. 解放军第三军医大学药学院生药学教研室,重庆市,400038
- 折叠
摘要
Abstract
BACKGROUND: Tumor stem cell plays an important role in the occurrence, development, metastasis and recurrence of tumor.However, due to conventional treatment cannot eliminate breast cancer stem cells, breast cancer stem cells have been assumed to be the origin of treatment failure in breast cancer.OBJECTIVE:To clarify the biological characteristics of breast cancer stem cells and the curative effects of targeted therapy for breast cancer by some drugs targeting, and then provides some advice for developing treatment strategies that may improve survival rate of breast cancer patients.METHODS: The articles related to the maker of breast cancer stem cells and identification, new drug for the targeting treatment of breast cancer stem cell from PubMed database between January 2000 and August 2010 were retrieved by the computer with the key words of "breast cancer, cancer stem cells, therapy" in English. Literatures were limited to English language. The literatures included clinical research, basic research, and reviews. A total of 204 literatu res were obtained from the computer screen,repetitive researches were excluded, and 33 documents of them were involved for further analysis.RESULTS AND CONCLUSION: Breast cancer stem cells are the first identified cancer stem cells in solid tumor. Breast cancer stem cells have been isolated successfully by many kinds of strategies, and biological characteristics are gradually studied deeply.Self-renewal and differentiation of breast cancer stem cells are regulated by microenvironment and many signaling pathways.Targeted therapy of breast cancer stem cells is gradually becoming the focus of tumor targeted therapy study.关键词
乳腺癌/肿瘤干细胞/放疗耐受性/化疗耐受性/靶向治疗分类
医药卫生引用本文复制引用
任远,李泽桂..基于乳腺癌干细胞的临床治疗进展[J].中国组织工程研究与临床康复,2011,15(6):1103-1106,4.
